NPCE Overview

NeuroPace, Inc. is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. The Company's RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders. The Company's RNS System includes its RNS neurostimulator, its cortical strip leads and depth leads, and its Patient Remote Monitor, as well as other implantable and non-implantable accessories. The Company's product offerings also include Physician Tablet, Patient Data Management System (PDMS) and nSight Platform, which facilitate ongoing patient monitoring and streamline patient support. The PDMS is an online database.

Wall Street analysts forecast NPCE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NPCE is19.17 USD with a low forecast of 16.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Neuropace Inc revenue for the last quarter amounts to 26.59M USD, increased 23.86

Neuropace Inc. EPS for the last quarter amounts to -0.08 USD, decreased -55.56

Neuropace Inc (NPCE) has 209 emplpoyees as of May 13 2026.

Today NPCE has the market capitalization of 622.99M USD.